VENLO, The Netherlands, January 18, 2017 /PRNewswire/ --
QIAGEN N.V. (Nasdaq: QGEN) (Frankfurt: QIA) plans as previously announced to release its report on results for the fourth quarter and full year 2016 on Wednesday, February 1, at approximately 22:00 Central European Time (CET) / 16:00 Eastern Time (ET). A conference call is planned for Thursday, February 2, at 15:30 CET / 9:30 ET hosted by Peer M. Schatz, Chief Executive Officer, and Roland Sackers, Chief Financial Officer.
Conference Call and Webcast Details
The conference call will begin at 15:30 CET / 9:30 ET on February 2, 2017.
Interested parties may listen to the call by dialing: +1 631 302 6547 (U.S.), +44 203 059 8128 (UK), +49 69 566 036 000 (Germany)
The webcast will be accessible at http://www.qiagen.com/de/about-us/investors/corporate-calendar.
A conference call replay will be available through February 9, 2017, by dialing:
+1 724 5589 653 (U.S.), +44 121 260 4861 (UK), +49 69 710 488 70 (Germany) (passcode: 706273#).
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharma and biotech companies) and Academia (life sciences research). As of September 30, 2016, QIAGEN employed approximately 4,600 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.
Vice President Corporate Communications and Investor Relations
Dr. Sarah Fakih
Associate Director Investor Relations
SOURCE QIAGEN N.V.